Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.9 EUR | -6.28% | -1.95% | +70.99% |
16/05 | Transcript : NewAmsterdam Pharma Company N.V. - Special Call | |
15/05 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+70.99% | 174.66Cr | |
+9.83% | 12TCr | |
+10.80% | 10TCr | |
-10.84% | 2.27TCr | |
+4.72% | 2.18TCr | |
-10.63% | 1.82TCr | |
-41.92% | 1.65TCr | |
-15.11% | 1.6TCr | |
+6.62% | 1.41TCr | |
+17.53% | 1.07TCr |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Names Juliette Audet Chief Business Officer